All GLP-1 medications from licensed 503A pharmacies Browse Products

Medication research visual for Semaglutide And Gallbladder?
Supporting image for Semaglutide And Gallbladder?.

Semaglutide And Gallbladder?

Semaglutide may increase the risk of gallbladder problems including gallstones, primarily due to rapid weight loss. Learn the signs, risk factors, and...

By Dr. Sarah Chen, PharmD|Reviewed by Dr. David Kim, MD, FACE||

Medically Reviewed

Written by Dr. Sarah Chen, PharmD · Reviewed by Dr. David Kim, MD, FACE

In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
Ozempic evidence source
Official source
Retatrutide evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Wegovy evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

Key Takeaway

Semaglutide may increase the risk of gallbladder problems including gallstones, primarily due to rapid weight loss. Learn the signs, risk factors, and how to protect yourself.

Semaglutide may increase the risk of gallbladder problems, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). This risk is primarily driven by rapid weight loss rather than a direct drug effect on the gallbladder. In clinical trials, gallbladder-related events occurred in roughly 1.5 to 2.6 percent of patients on higher semaglutide doses.

Detailed Answer

The connection between semaglutide and gallbladder issues is well documented in clinical trial data. In the STEP 1 trial[1] for semaglutide 2.4 mg (Wegovy), gallbladder-related adverse events were reported in approximately 2.6 percent of semaglutide patients compared to 1.2 percent on placebo. The SUSTAIN trials for lower semaglutide doses used for diabetes (Ozempic) reported lower rates, consistent with the finding that gallbladder risk correlates with the degree of weight loss.

Why Weight Loss Causes Gallbladder Problems

Gallstones form when the composition of bile changes. During rapid weight loss, the liver secretes more cholesterol into bile, while the gallbladder contracts less frequently because less food (especially fat) is being consumed. This combination of cholesterol-saturated bile sitting in a sluggish gallbladder creates ideal conditions for stone formation.

This isn't unique to semaglutide. Gallstone formation is a well-known complication of any method of rapid weight loss, including bariatric surgery, very low calorie diets, and other weight loss medications. The risk increases when patients lose more than 1.5 kilograms (about 3.3 pounds) per week over a sustained period.

Possible Direct Drug Effects

Some researchers have suggested that GLP-1 receptor agonists may also have a direct effect on gallbladder motility. GLP-1 receptors are present in the gallbladder, and activating them may reduce gallbladder contractions, contributing to bile stasis. But this direct pharmacological contribution is considered secondary to the weight-loss-driven mechanism.

Who Is at Higher Risk?

Several factors increase your baseline risk for gallbladder problems during semaglutide therapy:

  • Losing weight rapidly (more than 3 pounds per week sustained)
  • Being female (women develop gallstones at roughly twice the rate of men)
  • Being over age 40
  • Having a personal or family history of gallstones
  • Having obesity prior to treatment (already an independent risk factor for gallstones)
  • Following a very low-fat diet (the gallbladder needs some fat intake to contract and empty regularly)

Warning Signs to Watch For

Gallbladder symptoms can overlap with common semaglutide side effects, which makes it important to know the differences. Typical semaglutide nausea is mild to moderate, diffuse, and improves over time. Gallbladder pain is usually sudden, intense, localized to the upper right abdomen, and may radiate to the shoulder or back. It often occurs after fatty meals and can last 30 minutes to several hours. Fever, yellowing of skin or eyes (jaundice), and clay-colored stools are additional red flags that require immediate medical attention.

What You Need to Know

  • Gallbladder problems are an uncommon but recognized risk during semaglutide therapy, occurring in roughly 2 to 3 percent of patients at higher doses.
  • The risk is primarily driven by rapid weight loss, not a direct toxicity of the medication.
  • Including moderate amounts of healthy fat in your diet helps the gallbladder contract regularly and can reduce gallstone risk.
  • Report any sudden, severe upper right abdominal pain to your healthcare provider promptly.
  • Patients who have already had their gallbladder removed can safely take semaglutide without this particular risk.
  • Your physician may recommend a slower pace of weight loss or periodic ultrasound monitoring if you have existing gallbladder risk factors.

What are the signs of gallbladder problems on semaglutide?

The hallmark symptom is sudden, sharp pain in the upper right side of your abdomen, often radiating to your right shoulder blade or back. This pain typically occurs after eating, especially fatty meals, and lasts 30 minutes to several hours. Nausea, vomiting, fever, and jaundice (yellowing of the skin or eyes) may accompany the pain. If you experience these symptoms, contact your healthcare provider immediately, as untreated cholecystitis can lead to serious complications. For a complete cost breakdown, see our cheapest GLP-1 without insurance.

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.

Try the BMI Calculator →
GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Semaglutide And Gallbladder?

Can I take semaglutide if I have had my gallbladder removed?

Yes. If you have undergone a cholecystectomy (gallbladder removal), the risk of gallstones is eliminated because you no longer have a gallbladder in which stones can form. Semaglutide is considered safe for use in patients without a gallbladder. You may still experience GI side effects from semaglutide, but these are unrelated to gallbladder function. semaglutide side effects

Does eating fat help prevent gallbladder problems on semaglutide?

Including moderate amounts of healthy fat in your diet (olive oil, avocado, nuts, fatty fish) helps stimulate gallbladder contractions and prevent bile from becoming stagnant. Very low-fat diets can actually increase gallstone risk because the gallbladder doesn't empty frequently enough. Aim for balanced meals that include some fat at each meal rather than eliminating fat entirely.

Medical References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]

Take the Next Step

Our physician-supervised telehealth program monitors for gallbladder and other potential risks throughout your semaglutide treatment. FormBlends.com can connect you with a licensed provider who will review your risk factors, guide your treatment plan, and ensure your safety during therapy.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by Dr. Sarah Chen, PharmD

Clinical Pharmacist. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by Dr. David Kim, MD, FACE for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Physician-supervised GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $299/month with free shipping.

Next Best Reads

Free Tools

Physician-designed calculators to support your weight loss journey.